Sarepta Therapeutics (NASDAQ:SRPT)

CAPS Rating: 2 out of 5

A biopharmaceutical company developing therapeutic products principally based on third-generation NEUGENE antisense technology.

Recs

1
Player Avatar mjrruby (< 20) Submitted: 10/6/2009 4:04:11 PM : Outperform Start Price: $10.86 SRPT Score: +183.32

Just read Barons issue of Oct.5, 2009

Report this Post Reply

Featured Broker Partners


Advertisement